<- Go Home
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Market Cap
$307.0B
Volume
5.3M
Cash and Equivalents
$7.3B
EBITDA
$25.6B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$39.1B
Profit Margin
70.33%
52 Week High
$207.32
52 Week Low
$153.58
Dividend
3.78%
Price / Book Value
50.89
Price / Earnings
60.52
Price / Tangible Book Value
-3.20
Enterprise Value
$371.0B
Enterprise Value / EBITDA
14.31
Operating Income
$17.3B
Return on Equity
56.41%
Return on Assets
7.72
Cash and Short Term Investments
$7.3B
Debt
$71.3B
Equity
$6.1B
Revenue
$55.5B
Unlevered FCF
$19.4B
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium